Li, Jun http://orcid.org/0000-0002-6836-2716
Hubisz, Melissa J. http://orcid.org/0000-0002-9561-6830
Earlie, Ethan M. http://orcid.org/0000-0003-3039-9692
Duran, Mercedes A. http://orcid.org/0009-0002-9974-4095
Hong, Christy
Varela, Austin A. http://orcid.org/0000-0002-9068-7605
Lettera, Emanuele
Deyell, Matthew http://orcid.org/0009-0009-6543-1171
Tavora, Bernardo
Havel, Jonathan J. http://orcid.org/0000-0003-0951-510X
Phyu, Su M. http://orcid.org/0000-0003-1775-6966
Amin, Amit Dipak http://orcid.org/0000-0002-2613-2082
Budre, Karolina
Kamiya, Erina http://orcid.org/0000-0001-9048-5125
Cavallo, Julie-Ann
Garris, Christopher
Powell, Simon http://orcid.org/0000-0002-8183-4765
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Wen, Hannah
Bettigole, Sarah
Khan, Atif J.
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
Parkes, Eileen E.
Laughney, Ashley M. http://orcid.org/0000-0001-9435-953X
Bakhoum, Samuel F. http://orcid.org/0000-0002-4779-8422
Article History
Received: 9 December 2021
Accepted: 20 July 2023
First Online: 23 August 2023
Competing interests
: S.F.B. holds a patent related to some of the work described targeting CIN and the cGAS–STING pathway in advanced cancer. He owns equity in, receives compensation from, serves as a consultant for, and serves on the Scientific Advisory Board (SAB) and Board of Directors (BOD) of Volastra Therapeutics Inc., and serves on the SAB of Meliora Therapeutics. E.E.P. has served as a consultant for Boehringer Ingleheim. B.I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck. H.W. is an advisor for AstraZeneca and received honoraria from Roche. J.S.R.-F. consults for Goldman Sachs, Bain Capital, Repare Therapeutics, Personalis, Saga Diagnostics and Paige.AI; serves on the SAB of Repare Therapeutics, VolitionRx, Paige.AI, AstraZeneca, MSD, Personalis and Daiichi Sankyo; and serves on the BOD of Grupo OncoclĂnicas. S.B., J.J.H. and B.T. are employees of and own equity in Volastra Therapeutics Inc. C.G. consults for Cellino Biotech and Gardian Bio. The remaining authors declare no competing interests.